December 4, 2025 at 4:09 PM
December 4, 2025 at 4:07 PM
Lots of #sciencerockstar sightings at #CTAD2025
December 4, 2025 at 4:05 PM
Lots of #sciencerockstar sightings at #CTAD2025
Some preliminary data on CSF and plasma biomarkers of disease activity and neuroinflammation from the two evoke trials with oral semaglutide #Alzheimersdisease #CTAD2025 sciencehub.novonordisk.com/congresses/c... 🧪
December 4, 2025 at 7:47 PM
Some preliminary data on CSF and plasma biomarkers of disease activity and neuroinflammation from the two evoke trials with oral semaglutide #Alzheimersdisease #CTAD2025 sciencehub.novonordisk.com/congresses/c... 🧪
The FTD Disorders Registry was recently featured at #CTAD2025 in San Diego! Dr. Shana Dodge presented a poster showing how the Registry is helping accelerate clinical trial recruitment.
Read more: ftdregistry.org/press/ftd-di...
Read more: ftdregistry.org/press/ftd-di...
December 19, 2025 at 4:01 PM
The FTD Disorders Registry was recently featured at #CTAD2025 in San Diego! Dr. Shana Dodge presented a poster showing how the Registry is helping accelerate clinical trial recruitment.
Read more: ftdregistry.org/press/ftd-di...
Read more: ftdregistry.org/press/ftd-di...
It's a great day in San Diego for Day 2 of #CTAD2025! We look forward to sessions exploring the latest science. This afternoon, we will hold our working lunch on Driving Innovation where experts will discuss policy alignment with breakthroughs in biomarkers, AI, and precision medicine.
December 2, 2025 at 4:48 PM
It's a great day in San Diego for Day 2 of #CTAD2025! We look forward to sessions exploring the latest science. This afternoon, we will hold our working lunch on Driving Innovation where experts will discuss policy alignment with breakthroughs in biomarkers, AI, and precision medicine.
New study results indicate that lifestyle changes can protect aging brains. The U.S. POINTER study tested whether a structured, healthy lifestyle program could protect cognitive function in at-risk older adults. The answer is YES.
Explore this news and more from #CTAD2025: https://bit.ly/4pTAgoa
Explore this news and more from #CTAD2025: https://bit.ly/4pTAgoa
Breaking News Dispatch: New Findings on GLP-1 Drugs and Alzheimer's, Novel Treatments in Development, and More
Get the latest news from the 2025 Clinical Trials on Alzheimer's Disease (CTAD) conference.
www.brightfocus.org
December 10, 2025 at 6:27 PM
New study results indicate that lifestyle changes can protect aging brains. The U.S. POINTER study tested whether a structured, healthy lifestyle program could protect cognitive function in at-risk older adults. The answer is YES.
Explore this news and more from #CTAD2025: https://bit.ly/4pTAgoa
Explore this news and more from #CTAD2025: https://bit.ly/4pTAgoa
At #CTAD2025, Novo Nordisk shared new phase 3 results from Evoke/Evoke+ trials, offering important insights that underscore a critical shift toward the next era of drug development, which will target the underlying biology of this complex disease.
bit.ly/4iMH1WH
bit.ly/4iMH1WH
December 4, 2025 at 3:15 PM
At #CTAD2025, Novo Nordisk shared new phase 3 results from Evoke/Evoke+ trials, offering important insights that underscore a critical shift toward the next era of drug development, which will target the underlying biology of this complex disease.
bit.ly/4iMH1WH
bit.ly/4iMH1WH
The EVOKE trials found that semaglutide, the GLP-1 drug behind several popular diabetes and weight loss medications, did not meaningfully slow cognitive decline in people with Alzheimer’s disease.
Explore this research and more news from #CTAD2025. https://bit.ly/48KgAxG
Explore this research and more news from #CTAD2025. https://bit.ly/48KgAxG
Breaking News Dispatch: New Findings on GLP-1 Drugs and Alzheimer's, Novel Treatments in Development, and More
Get the latest news from the 2025 Clinical Trials on Alzheimer's Disease (CTAD) conference.
www.brightfocus.org
December 17, 2025 at 12:09 AM
The EVOKE trials found that semaglutide, the GLP-1 drug behind several popular diabetes and weight loss medications, did not meaningfully slow cognitive decline in people with Alzheimer’s disease.
Explore this research and more news from #CTAD2025. https://bit.ly/48KgAxG
Explore this research and more news from #CTAD2025. https://bit.ly/48KgAxG
📢#CTAD2025 is just two weeks away!
As we gear up to connect with leaders and researchers advancing Alzheimer’s disease diagnosis and research, we’re excited to launch our redesigned web experience – live today
🔗Explore now: www.alzpath.bio
Attending CTAD? Let’s connect: inquiry@alzpath.bio
As we gear up to connect with leaders and researchers advancing Alzheimer’s disease diagnosis and research, we’re excited to launch our redesigned web experience – live today
🔗Explore now: www.alzpath.bio
Attending CTAD? Let’s connect: inquiry@alzpath.bio
November 20, 2025 at 8:15 PM
📢#CTAD2025 is just two weeks away!
As we gear up to connect with leaders and researchers advancing Alzheimer’s disease diagnosis and research, we’re excited to launch our redesigned web experience – live today
🔗Explore now: www.alzpath.bio
Attending CTAD? Let’s connect: inquiry@alzpath.bio
As we gear up to connect with leaders and researchers advancing Alzheimer’s disease diagnosis and research, we’re excited to launch our redesigned web experience – live today
🔗Explore now: www.alzpath.bio
Attending CTAD? Let’s connect: inquiry@alzpath.bio
We’re headed to #CTAD2025 in San Diego!
ALZpath will join global leaders in Alzheimer’s disease research and diagnostics to discuss advances in #pTau217 and blood-based biomarkers.
Attending? Let’s connect — reach out at inquiry@alzpath.bio to schedule a meeting.
#AlzheimersDisease #Research
ALZpath will join global leaders in Alzheimer’s disease research and diagnostics to discuss advances in #pTau217 and blood-based biomarkers.
Attending? Let’s connect — reach out at inquiry@alzpath.bio to schedule a meeting.
#AlzheimersDisease #Research
November 4, 2025 at 2:53 AM
We’re headed to #CTAD2025 in San Diego!
ALZpath will join global leaders in Alzheimer’s disease research and diagnostics to discuss advances in #pTau217 and blood-based biomarkers.
Attending? Let’s connect — reach out at inquiry@alzpath.bio to schedule a meeting.
#AlzheimersDisease #Research
ALZpath will join global leaders in Alzheimer’s disease research and diagnostics to discuss advances in #pTau217 and blood-based biomarkers.
Attending? Let’s connect — reach out at inquiry@alzpath.bio to schedule a meeting.
#AlzheimersDisease #Research
GLP-1 therapies are attracting attention and traction in Alzheimer’s research, but vascular co-pathology remains a critical factor in trial design. In the run-up to #CTAD2025, IXICO CSO Robin Wolz explains why vascular phenotyping matters.
Read more: ixico.com/news-and-res...
Read more: ixico.com/news-and-res...
December 1, 2025 at 10:56 AM
GLP-1 therapies are attracting attention and traction in Alzheimer’s research, but vascular co-pathology remains a critical factor in trial design. In the run-up to #CTAD2025, IXICO CSO Robin Wolz explains why vascular phenotyping matters.
Read more: ixico.com/news-and-res...
Read more: ixico.com/news-and-res...
We’re heading to #CTAD2025 next week in San Diego (Dec 1–4)!
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st (3:00 PM) – Dec 2nd (5:30 PM)
📩 Connect: ixico.com/contact-us
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st (3:00 PM) – Dec 2nd (5:30 PM)
📩 Connect: ixico.com/contact-us
November 26, 2025 at 11:18 AM
We’re heading to #CTAD2025 next week in San Diego (Dec 1–4)!
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st (3:00 PM) – Dec 2nd (5:30 PM)
📩 Connect: ixico.com/contact-us
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st (3:00 PM) – Dec 2nd (5:30 PM)
📩 Connect: ixico.com/contact-us
Let’s connect at #CTAD2025 (Dec 1–4)
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st–2nd
📩 ixico.com/contact-us
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st–2nd
📩 ixico.com/contact-us
November 19, 2025 at 12:23 PM
Let’s connect at #CTAD2025 (Dec 1–4)
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st–2nd
📩 ixico.com/contact-us
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st–2nd
📩 ixico.com/contact-us
We’re attending #CTAD2025 in San Diego (Dec 1–4)!
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st (3:00 PM) – Dec 2nd (5:30 PM)
📩 Connect: ixico.com/contact-us
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st (3:00 PM) – Dec 2nd (5:30 PM)
📩 Connect: ixico.com/contact-us
November 11, 2025 at 2:10 PM
We’re attending #CTAD2025 in San Diego (Dec 1–4)!
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st (3:00 PM) – Dec 2nd (5:30 PM)
📩 Connect: ixico.com/contact-us
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st (3:00 PM) – Dec 2nd (5:30 PM)
📩 Connect: ixico.com/contact-us
New data presented at #CTAD2025 📊
Etalanetug cut tau pathology biomarkers fast in dominantly inherited #Alzheimer
Key Changes:
🧬 CSF eMTBR-tau243 ↓ 62%
🩸 Plasma eMTBR-tau243 ↓ 78%
Read more here: www.neurologylive.com/view/ctad-po...
#AD #Neurology #TAU #BrainHealth #Conference #Coverage #Neuro
Etalanetug cut tau pathology biomarkers fast in dominantly inherited #Alzheimer
Key Changes:
🧬 CSF eMTBR-tau243 ↓ 62%
🩸 Plasma eMTBR-tau243 ↓ 78%
Read more here: www.neurologylive.com/view/ctad-po...
#AD #Neurology #TAU #BrainHealth #Conference #Coverage #Neuro
CTAD Poster Shows Etalanetug Reduced Tau Pathology Biomarkers in Dominantly Inherited Alzheimer Disease | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Treatment with etalanetug reduced cerebrospinal fluid eMTBR-tau243 by 62% and plasma eMTBR-tau243 by 78% at 3 months in patients with dominantly inherited Alzheimer disease.
www.neurologylive.com
December 3, 2025 at 2:08 PM
New data presented at #CTAD2025 📊
Etalanetug cut tau pathology biomarkers fast in dominantly inherited #Alzheimer
Key Changes:
🧬 CSF eMTBR-tau243 ↓ 62%
🩸 Plasma eMTBR-tau243 ↓ 78%
Read more here: www.neurologylive.com/view/ctad-po...
#AD #Neurology #TAU #BrainHealth #Conference #Coverage #Neuro
Etalanetug cut tau pathology biomarkers fast in dominantly inherited #Alzheimer
Key Changes:
🧬 CSF eMTBR-tau243 ↓ 62%
🩸 Plasma eMTBR-tau243 ↓ 78%
Read more here: www.neurologylive.com/view/ctad-po...
#AD #Neurology #TAU #BrainHealth #Conference #Coverage #Neuro
December 4, 2025 at 4:03 PM
Three ancillary studies to the U.S. POINTER trial collectively demonstrated that a structured 2-year lifestyle intervention for older adults at increased risk of cognitive decline led to better overall health. #CTAD2025
www.medpagetoday.com/meetingcover...
www.medpagetoday.com/meetingcover...
Cognitive Intervention Does More Than Defend Against Dementia
Sleep, brain resilience, and blood flow improved with structured POINTER program
www.medpagetoday.com
December 4, 2025 at 9:51 PM
Three ancillary studies to the U.S. POINTER trial collectively demonstrated that a structured 2-year lifestyle intervention for older adults at increased risk of cognitive decline led to better overall health. #CTAD2025
www.medpagetoday.com/meetingcover...
www.medpagetoday.com/meetingcover...
Once again, we participate at the #CTAD2025!
This year, @gsalvado.bsky.social gave an oral presentation about the use of blood-based biomarkers and their key role in the clinical trials field.
www.barcelonabeta.org/en/news/news...
This year, @gsalvado.bsky.social gave an oral presentation about the use of blood-based biomarkers and their key role in the clinical trials field.
www.barcelonabeta.org/en/news/news...
We present new advances in blood-based biomarkers at CTAD 2025
Dr. Gemma Salvadó presented an oral communication at the 18th edition of the conference dedicated to clinical trials on Alzheimer's disease.
www.barcelonabeta.org
December 9, 2025 at 8:16 AM
Once again, we participate at the #CTAD2025!
This year, @gsalvado.bsky.social gave an oral presentation about the use of blood-based biomarkers and their key role in the clinical trials field.
www.barcelonabeta.org/en/news/news...
This year, @gsalvado.bsky.social gave an oral presentation about the use of blood-based biomarkers and their key role in the clinical trials field.
www.barcelonabeta.org/en/news/news...